Education
About Us
Working with TipRanks
Follow Us
ProKidney (PROK)
NASDAQ:PROK
PROK Stock Chart & Stats
$2.18
-$0.14(-7.65%)
At close: 4:00 PM EST
$2.18
-$0.14(-7.65%)
Day’s Range― - ―
52-Week Range$0.46 - $7.13
Previous CloseN/A
Volume58.77K
Average Volume (3M)1.13M
Market Cap
$685.90M
Enterprise Value$0.00
Total Cash (Recent Filing)$271.73M
Total Debt (Recent Filing)$4.24M
Price to Earnings (P/E)―
Beta1.83
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding141,545,440
10 Day Avg. Volume951,570
30 Day Avg. Volume1,125,455
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)-0.17
Price to Sales (P/S)2177.35
P/FCF Ratio-1.06
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$5.33Price Target Upside144.50% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)-0.61
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial EnrollmentA large majority of participants required for the accelerated approval efficacy analysis are enrolled, demonstrating strong trial momentum that supports a timely readout.
Financial RunwayCompany guidance indicating cash runway into mid-2027 supports continued development and reduces near-term financing pressure for pivotal programs.
Trial Statistical PowerBuilt-in statistical power in the pivotal trial supports the ability to detect the regulator-recommended eGFR slope difference, increasing confidence in a meaningful efficacy signal.
Bears Say
Binary Trial Outcome VolatilityReliance on a single surrogate-driven pivotal readout creates a binary outcome that could trigger sharp share price swings around the trial result.
Commercialization Pathway UncertaintyMissing the surrogate threshold could jeopardize the accelerated approval pathway and delay or prevent a biologics license submission and commercialization plans.
Regulatory Threshold RiskRegulatory approval hinges on meeting a specific surrogate endpoint threshold, creating significant outcome and approval risk if the threshold is not achieved.
ProKidney News
PROK FAQ
What was ProKidney’s price range in the past 12 months?
ProKidney lowest stock price was $0.46 and its highest was $7.13 in the past 12 months.
What is ProKidney’s market cap?
ProKidney’s market cap is $685.90M.
When is ProKidney’s upcoming earnings report date?
ProKidney’s upcoming earnings report date is May 08, 2026 which is in 111 days.
How were ProKidney’s earnings last quarter?
ProKidney released its earnings results on Nov 18, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.133 by $0.013.
Is ProKidney overvalued?
According to Wall Street analysts ProKidney’s price is currently Undervalued.
Does ProKidney pay dividends?
ProKidney does not currently pay dividends.
What is ProKidney’s EPS estimate?
ProKidney’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ProKidney have?
ProKidney has 141,545,440 shares outstanding.
What happened to ProKidney’s price movement after its last earnings report?
ProKidney reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.133. Following the earnings report the stock price went up 1.754%.
Which hedge fund is a major shareholder of ProKidney?
Currently, no hedge funds are holding shares in PROK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProKidney Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.33 (144.50% Upside)
$5.33 (144.50% Upside)
Blogger Sentiment
Bullish
PROK Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 17.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 8.5%
Last 30 Days ▼ 8.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.30%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-25.94%
Trailing 12-Months
Company Description
ProKidney
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
PROK Stock 12 Month Forecast
Average Price Target
$5.33
▲(144.50% Upside)
Technical Analysis
Rezolute
―
Urogen Pharma
―
Phathom Pharmaceuticals
―
Relay Therapeutics
―
Nurix Therapeutics
―
Ownership Overview
Currently, No data available
---